<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE310nnn/GSE310965/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310965</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Islet-Intrinsic Sex Differences in Inflammatory Signaling Contribute to Autoimmune Diabetes Susceptibility</name><description>Whereas most autoimmune diseases exhibit female predominance, type 1 diabetes (T1D) occurs more frequently in males after puberty, suggesting a role for sex hormones in disease modification. Because islet β cells actively shape local immune responses, we hypothesized that sex-specific islet responses to inflammation contribute to this disparity. Using transcriptomic and proteomic analyses of human islets from male and female donors, we found that male islets exhibited a more aggressive response to proinflammatory cytokines, characterized by greater induction of interferon signaling and suppression of developmental signaling compared to female islets. Treatment of human islets and mouse β cells with the sex hormone 17β-estradiol (E2) suppressed inflammatory signaling and markers of β-cell maturity while enhancing developmental gene programs. Complementary studies in non-obese diabetic (NOD) mice showed that E2 treatment reduced diabetes incidence and limited progression to severe insulitis. Islet single-cell RNA sequencing revealed that E2 treatment of NOD mice suppressed interferon signaling, chemokine production, and antigen presentation in β cells, while reducing activation and cytotoxicity pathways in immune cells. In an aggressive adoptive transfer model, E2 pretreatment of the recipient mice attenuated hyperglycemia. These findings support a model in which estradiol-mediated β-cell reprogramming reduces β-cell immunogenicity and promotes local immune tolerance, offering mechanistic insight into sex-biased T1D susceptibility.</description><dates><publication>2026/05/17</publication></dates><accession>GSE310965</accession><cross_references><GSM>GSM9313358</GSM><GSM>GSM9313357</GSM><GSM>GSM9313359</GSM><GSM>GSM9313398</GSM><GSM>GSM9313354</GSM><GSM>GSM9313353</GSM><GSM>GSM9313397</GSM><GSM>GSM9313356</GSM><GSM>GSM9313355</GSM><GSM>GSM9313350</GSM><GSM>GSM9313394</GSM><GSM>GSM9313393</GSM><GSM>GSM9313352</GSM><GSM>GSM9313396</GSM><GSM>GSM9313395</GSM><GSM>GSM9313351</GSM><GSM>GSM9313390</GSM><GSM>GSM9313392</GSM><GSM>GSM9313391</GSM><GSM>GSM9313369</GSM><GSM>GSM9313368</GSM><GSM>GSM9313365</GSM><GSM>GSM9313364</GSM><GSM>GSM9313367</GSM><GSM>GSM9313366</GSM><GSM>GSM9313361</GSM><GSM>GSM9313360</GSM><GSM>GSM9313363</GSM><GSM>GSM9313362</GSM><GSM>GSM9313339</GSM><GSM>GSM9313379</GSM><GSM>GSM9313376</GSM><GSM>GSM9313375</GSM><GSM>GSM9313378</GSM><GSM>GSM9313377</GSM><GSM>GSM9313372</GSM><GSM>GSM9313371</GSM><GSM>GSM9313374</GSM><GSM>GSM9313373</GSM><GSM>GSM9313370</GSM><GSM>GSM9313347</GSM><GSM>GSM9313346</GSM><GSM>GSM9313349</GSM><GSM>GSM9313348</GSM><GSM>GSM9313343</GSM><GSM>GSM9313387</GSM><GSM>GSM9313386</GSM><GSM>GSM9313342</GSM><GSM>GSM9313389</GSM><GSM>GSM9313345</GSM><GSM>GSM9313388</GSM><GSM>GSM9313344</GSM><GSM>GSM9313383</GSM><GSM>GSM9313382</GSM><GSM>GSM9313341</GSM><GSM>GSM9313385</GSM><GSM>GSM9313384</GSM><GSM>GSM9313340</GSM><GSM>GSM9313381</GSM><GSM>GSM9313380</GSM><GPL>34281</GPL><GSE>310965</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>